RT Journal Article SR Electronic T1 Transmission of SARS-CoV-2 within households: a prospective cohort study in the Netherlands and Belgium – Interim results JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.04.23.21255846 DO 10.1101/2021.04.23.21255846 A1 JDM Verberk A1 MLA de Hoog A1 I Westerhof A1 S Van Goethem A1 C Lammens A1 M Ieven A1 E de Bruin A1 J Bielicki A1 S Coenen A1 J van Beek A1 M Bonten A1 H Goossens A1 PCJL Bruijning-Verhagen YR 2021 UL http://medrxiv.org/content/early/2021/04/26/2021.04.23.21255846.abstract AB Background Household transmission studies are useful to obtain granular data on SARS-CoV-2 transmission dynamics and to gain insight into the main determinants. In this interim report we investigated secondary attack rates (SAR) by household and subject characteristics in the Netherlands and Belgium.Methods Households with a real-time reverse transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 index case were enrolled <48 hours following report of the positive test result. Daily symptom follow-up, standardized nose-throat sampling at enrollment and at new-onset acute respiratory illness (ARI) and paired dried blood spots (DBS) were collected from each participant. Children 0-2 years of age were additionally requested to collect a stool sample 7 days after enrollment and at new-onset of ARI. Swabs and stool samples were tested by RT-PCR for virus detection and DBS by multiplex protein microarray for detection of SARS-CoV-2 antibodies. The SAR was calculated 1) per-household as the proportion of households with ≥1 secondary SARS-CoV-2 case and 2) per-person as the probability of infection in household members at risk. We explored differences in SARs by household and subject characteristics.Results This analysis includes 117 households that completed follow-up between April-December 2020. Among 382 subjects, 74 secondary infections were detected, of which 13 (17.6%) were asymptomatic and 20 (27.0%) infections were detected by seroconversion only. Of cases detected by RT-PCR, 50 (67.6%) were found at enrollment. The household SAR was 44.4% (95%-CI: 35.4-53.9%) and was higher for index cases meeting the ARI case definition (52.3%; 95%-CI 41.4-62.9%) compared to mildly symptomatic (22.2%; 95%-CI: 9.4-42.7%) and asymptomatic index cases (0.0%; 95%-CI: 0.0-80.2%). The per-person SAR was 27.9% (95%-CI: 22.7-33.8%). Transmission was lowest from child to parent (9.1%; 95%-CI: 2.4-25.5%) and highest from parent to child (28.1%; 95%-CI: 19.7-38.4%) and in children 6-12 years (34.2%; 95%-CI: 20.1-51.4%). Among 141 subjects with RT-PCR confirmed SARS-CoV-2 infections, seroconversion was detected in 111 (78.7%).Conclusion We found a high household SAR, with the large majority of transmissions detected early after identification of the index case. Our findings confirm differential SAR by symptom status of the index. In almost a quarter of RT-PCR positive cases, no antibodies were detected. Other factors influencing transmission will be further explored as more data accumulate.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work forms part of RECOVER (Rapid European COVID-19 Emergency Response research). RECOVER is funded by the EU Horizon 2020 research and innovation programme under grant agreement number 101003589.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medical Ethical Committee Utrecht (NL) and Medical Ethics Committee UZA Antwerp (BE) provided review and ethical approval for this study (Reference number 20-185/D and 20/14/177 respectively).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAs this is an ongoing study the data is not yet available on a research data repository.